ArticleScientific reports2026
Short-term vaginal prasterone therapy induces steroid receptor modulation and extracellular matrix remodeling in human vaginal mucosa.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prasterone (dehydroepiandrosterone, DHEA) is increasingly used in the treatment of genitourinary syndrome of menopause (GSM), although its molecular effects on vaginal tissue remain insufficiently characterized. This prospective study evaluated the short-term impact of vaginal prasterone on steroid receptor expression, epithelial morphology, extracellular matrix composition, and the proteomic profile of the vaginal mucosa. Ten women aged 41-67 years received intravaginal prasterone (6.5 mg daily) for eight weeks. Vaginal biopsies were obtained before and after treatment, and serum estradiol and DHEA-S levels were assessed. Immunohistochemical analysis demonstrated a significant increase in cumulative ERα expression across epithelial layers (p = 0.0379), with the most pronounced changes in the superficial epithelium and stromal compartment. Progesterone receptor expression showed stromal upregulation accompanied by epithelial downregulation. Epithelial thickness increased by 17.5 μm following therapy. Proteomic analysis using LC-MS/MS identified 87 proteins with altered abundance, including enrichment of extracellular matrix components and upregulation of collagen IV (COL4A1 and COL4A2). In contrast, several inflammation- and remodeling-related proteins, including IL18, LCN2, SERPINE2, and PRSS27, were downregulated. These findings indicate that short-term vaginal prasterone therapy promotes steroid receptor modulation and extracellular matrix remodeling in human vaginal mucosa while reducing inflammatory signaling pathways. Patient-reported outcomes assessed using the WHOQOL-BREF questionnaire indicated a trend toward improvement in quality of life following treatment, with the largest median increases observed in the physical (Domain 1) and environmental (Domain 4) domains. However, these changes did not reach statistical significance (p > 0.05), and no significant differences were observed in overall quality of life or perceived health status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.